OptiNose (NASDAQ:OPTN) Receives "Buy" Rating from HC Wainwright

OptiNose (NASDAQ:OPTN - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They currently have a $5.00 price objective on the stock. HC Wainwright's target price points to a potential upside of 321.94% from the stock's previous close.

Separately, Lake Street Capital upped their price target on shares of OptiNose from $3.00 to $4.00 and gave the company a "buy" rating in a research note on Monday, March 18th.

OptiNose Trading Up 4.9 %

Shares of OptiNose stock traded up $0.06 on Wednesday, reaching $1.19. 568,954 shares of the company were exchanged, compared to its average volume of 887,269. OptiNose has a one year low of $0.80 and a one year high of $2.10. The company has a 50-day moving average of $1.32 and a 200 day moving average of $1.31. The company has a market capitalization of $133.95 million, a price-to-earnings ratio of -3.48 and a beta of -0.10.

OptiNose (NASDAQ:OPTN - Get Free Report) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. The firm had revenue of $19.87 million during the quarter, compared to the consensus estimate of $19.90 million. During the same period last year, the business earned ($0.17) EPS. Analysts predict that OptiNose will post -0.26 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Michael F. Marino III sold 15,059 shares of OptiNose stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $1.88, for a total value of $28,310.92. Following the completion of the sale, the insider now directly owns 602,268 shares in the company, valued at $1,132,263.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, insider Michael F. Marino III sold 15,059 shares of the business's stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $1.88, for a total value of $28,310.92. Following the completion of the transaction, the insider now owns 602,268 shares of the company's stock, valued at $1,132,263.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Ramy A. Mahmoud sold 19,198 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $1.88, for a total transaction of $36,092.24. Following the sale, the chief executive officer now owns 1,331,278 shares in the company, valued at $2,502,802.64. The disclosure for this sale can be found here. Insiders sold 36,602 shares of company stock worth $68,812 in the last quarter. 2.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in OPTN. FMR LLC lifted its stake in OptiNose by 0.3% during the third quarter. FMR LLC now owns 14,848,870 shares of the company's stock worth $18,264,000 after purchasing an additional 47,564 shares during the last quarter. MVM Partners LLC acquired a new position in OptiNose during the fourth quarter worth about $18,768,000. Vanguard Group Inc. lifted its holdings in shares of OptiNose by 1.5% in the first quarter. Vanguard Group Inc. now owns 4,242,610 shares of the company's stock worth $6,194,000 after acquiring an additional 62,906 shares during the last quarter. Kingdon Capital Management L.L.C. boosted its stake in shares of OptiNose by 5.4% in the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,899,237 shares of the company's stock valued at $5,030,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Easterly Investment Partners LLC increased its position in OptiNose by 34.0% during the 1st quarter. Easterly Investment Partners LLC now owns 2,038,039 shares of the company's stock worth $2,976,000 after purchasing an additional 516,730 shares in the last quarter. 85.60% of the stock is owned by institutional investors.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.